Drug reformulation for a neglected disease. The NANOHAT project to develop a safer more effective sleeping sickness drug.

ABSTRACT:

Background

Human African trypanosomiasis (HAT or sleeping sickness) is caused by the parasite Trypanosoma brucei sspp. The disease has two stages, a haemolymphatic stage after the bite of an infected tsetse fly, followed by a central nervous system stage where the parasite penetrates the brain, causing death if untreated. Treatment is stage-specific, due to the blood-brain barrier, with less toxic drugs such as pentamidine used to treat stage 1. The objective of our research programme was to develop an intravenous formulation of pentamidine which increases CNS exposure by some 10-100 fold, leading to efficacy against a model of stage 2 HAT. This target candidate profile is in line with drugs for neglected diseases inititative recommendations.

Methodology

To do this, we evalu

SUBMITTER: Sanderson L 

PROVIDER: S-EPMC8078842 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature